Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells

This publication has 23 references indexed in Scilit:

• APO866 activity in hematologic malignancies: a preclinical in vitro study
  Blood, 2009
• The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies
  Blood, 2009
• Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
  Nature Reviews Drug Discovery, 2008
• The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
  Investigational New Drugs, 2007
• Nutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival
  Cell, 2007
• Autophagy in metazoans: cell survival in the land of plenty
  Nature Reviews Molecular Cell Biology, 2005
• Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy
  Clinical Cancer Research, 2005
• Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis
  Blood, 2005
• TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation
  Apoptosis, 2005
• Structural role of disulfide bridges in the cyclic ADP‐ribose related bifunctional ectoenzyme CD38
  FEBS Letters, 1995